Millions Trapped: The Hidden Crisis of Nasal Decongestant Spray Addiction in Britain

Imagine waking up each day with a single, overriding thought: the desperate need to reach for a humble £3 bottle of nasal spray. For 30-year-old Charlotte Johnstone, this isn’t a fleeting worry; it’s been her reality for 23 years, a silent addiction that has reshaped her life since childhood. Her story, though deeply personal, echoes a far wider, unseen public health crisis gripping Britain, as revealed by a joint investigation from ITV News and Ipsos.

This isn’t merely about convenience; it’s about a chemical dependency that traps millions, often without them ever realizing the very remedy they seek for relief is the architect of their suffering. The alarming findings indicate that more than one in five adults who have used decongestant nasal sprays have done so for longer than the recommended seven-day limit set by the NHS and manufacturers. This places an estimated 5.5 million people at significant risk of developing a serious dependency, leading to consequences that stretch far beyond a blocked nose, encompassing anxiety, panic attacks, chronic sleep deprivation, and, in some severe cases, the need for surgical intervention.

The Rebound Congestion Trap: How Relief Becomes Entrapment

The mechanism behind nasal decongestant spray addiction is a cruel paradox of modern medicine. Sprays containing active ingredients like xylometazoline or oxymetazoline, commonly found in popular brands such as Vicks Sinex, Otrivine, and Sudafed, work by constricting blood vessels in the nasal passages. This offers immediate, albeit temporary, relief from congestion, allowing users to breathe freely for a short period.

However, prolonged use beyond the advised seven days triggers a condition medically known as rhinitis medicamentosa, or ‘rebound congestion.’ In this scenario, the delicate nasal tissues adapt to the constant vasoconstriction. When the medication wears off, or a user attempts to stop, the nasal passages react by becoming even more inflamed and congested than they were originally. It’s a vicious cycle: the only way to alleviate this intensified congestion is to use more spray, thereby deepening the dependency with each application. This physiological loop is incredibly difficult to break, creating a powerful psychological reliance alongside the physical one.

Despite explicit warnings on packaging and from health authorities like the NHS, the practice of overuse persists on a staggering scale. A survey by the Royal Pharmaceutical Society, published on January 8, 2026, highlighted a critical blind spot: nearly three-quarters (74%) of community pharmacists believe product packaging is insufficiently clear about the seven-day restriction. Furthermore, a concerning 59% of pharmacists felt that patients are entirely unaware of the rebound congestion risk, suggesting millions are inviting severe consequences through sheer ignorance.

Yet, this crisis isn’t invisible to those on the front lines. An extraordinary 63% of the 309 community pharmacists surveyed reported intervening in suspected cases of overuse. These interventions often involve recommending alternative treatments or, in some instances, refusing to sell the product outright. These professionals are witnessing the human toll of this hidden dependency up close, regularly.

The Human Cost: Stories from a Life Held Captive

Charlotte Johnstone’s experience vividly illustrates the psychological imprisonment that accompanies chemical dependency. She has been using her spray multiple times daily since the age of seven, a habit that now costs her around £30 per month. While this financial burden might seem modest, the immeasurable cost to her quality of life is profound. ‘I can’t sleep without having it, I wake up and the first thing I do is have my nasal spray,’ she revealed to ITV News. The simple act of eating becomes ‘claustrophobic’ when congested, and the mere prospect of being without her spray triggers avoidance behaviors that have fundamentally restructured her social existence.

Perhaps most unsettling is her resigned acceptance of potential internal damage. ‘I go through stages of losing my sense of smell. I know it’s doing something but I don’t know what,’ she confessed. Yet, the fear of withdrawal proves more potent than the fear of continued use. ‘Going cold turkey, you’ve got to be really brave for that. I’d have to book a lot of time off work. And it’s very scary to think about,’ she explained.

Following ITV News’s initial investigation in April 2025, thousands of viewers came forward with remarkably similar stories. One correspondent recounted spending six agonizing months with both nostrils completely blocked after overuse, declaring, ‘this is no joke. It was the worst six months of my life.’ Another, dependent for fifteen years, experiences ‘a full-blown panic attack if I go anywhere and forget it.’ Most damning was the account of a patient who sought help from their GP only to be met with dismissal: ‘I went to the GP because of my dependency on nasal spray and she laughed in my face.’

A System Failing Patients: The Urgent Call for Change

Professor Amira Guirguis, chief scientist at the Royal Pharmaceutical Society, has emerged as a leading voice demanding systemic change. ‘Nasal decongestant sprays can be helpful for short-term relief, but using them for longer than seven days can make your congestion significantly worse,’ she stated. ‘Our research shows that many people are unaware of this risk, which means they may continue using these sprays without realising they could be prolonging their symptoms. We’d like to see clearer warnings on the packaging which you can’t miss and greater awareness of the seven-day limit.’

Olivier Picard, chair of the National Pharmacy Association, added crucial context, highlighting a troubling gap in patient care: ‘When a patient buys medication off the shelf in places such as a supermarket or a petrol station, they may be unaware of the potential side effects of what they are taking or how to safely take the medicine.’ This observation underscores a significant challenge: while pharmacists can intervene, countless individuals purchase these sprays in non-pharmacy settings, entirely beyond professional guidance.

The Royal Pharmaceutical Society and other health chiefs have warned that prolonged overuse can even lead to ‘irreversible damage to the airways’ by irritating the sensitive blood vessels in the nose, causing persistent swelling and exacerbating the vicious cycle of dependency. This serious warning amplifies the urgency of the situation, underscoring that the consequences extend beyond mere discomfort.

Despite the grim picture, hope exists. Safe and effective alternatives are readily available. These include steroid nasal sprays, which address inflammation directly, saline rinses for gentle clearing, menthol inhalations, and simple steam therapy. For those already caught in the grip of dependency, recovery is typically achievable within days of ceasing use, with relapse rates proving exceptionally rare. The medical pathway forward is clear and well-defined.

What remains uncertain is whether sufficient urgency and political will can be marshaled to implement the necessary changes. Without clearer warnings, enhanced public education, and better oversight of sales channels, millions more risk becoming trapped, much like Charlotte Johnstone, prisoners to a tiny bottle sitting silently on their bedside table. The time for decisive action to avert a growing public health crisis is now.